Scope of analysis		Notes				
Unit of analysis (full organization or program of a larger organization)	SCI unrestricted					
Analysis 'as of' date	June 30, 2017					
End date of the analysis: GiveWell's next allocation						
decision	November 30, 2018					
Date by which funds need to be recevied (or committed) for them to impact plans prior to GiveWell's next funding allocation	January 31, 2018					
Funds on hand	Amount	Notes				
Funds in the bank for SCI unrestricted as of June 30, 2017	\$17,241,296 [1]					
		SCI provided a list of the funding it has committed to future activities at http://givewell.org/files/DWDA%				
Of funds in the bank for SCI unrestricted, amount committed to future activities	\$14,764,294 [2]	202009/SCI/SCI_Commitments_July_2017_to _March_2018_Redacted.xlsx				
Of funds in the bank for SCI unrestricted, funds held in reserve	\$1,640.341 [3]	Funds in reserve are funds that are not expected to be spent unless there is a major revenue shortfall				
Uncommitted, unreserved funds in the bank		Calculation				
		Are there any reasons why last year's revenue				
Projected revenue	Value from same period in previous year	is not a reasonable projection for next year (ignoring variation in GiveWell-influenced funding)?	Projection	Notes		
Total revenue for SCI unrestricted, between July 1, 2016 and January 31, 2017	\$15,130,464 [4]	No [5]	\$15,130,464			
Total GiveWell-driven funding that reached the organization between July 1, 2016 and January 31, 2017	\$13,321,045 [6]	-	-			
Projected revenue from donors who are not influenced by GiveWell's research, between June 30, 2017 and January 31, 2018	-	-	\$1,809,418	Calculation		
Funding held by GiveWell as of June 30, 2017 for supporting SCI unrestricted	-	-	\$32,000	From GiveWell's internal donation records		
Projected revenue from donors who give based on GiveWell's top charity list, but do not follow our recommendation for marginal funding, between June 30, 2017 and January 31, 2018	\$945,000 [7]			GiveWell maintains both a list of all top charities that meet our criteria and a recommendation for which charity or charities to support to maximize the impact of additional donations, given the cost-effectiveness of remaining funding gaps.		
, , , , , , , , , , , , , , , , , , , ,	,,		, , , , , ,	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		
		Assets and projected revenue, b			Exchange rate as	1.34
	2018/19	2019/20	2020/21	Total		
Unrestricted (excluding GiveWell's 2017 recommendation)	\$3,623,079	\$1,809,418		\$7,241,916		
DFID (rough SCI projection)	\$6,700,000	\$6,700,000	\$6,700,000	\$20,100,000		
END Fund (rough SCI projection)						
	\$178,666	\$178,666	\$178,666	\$535,999		
CIFF (rough SCI projection)	\$178,666 \$452,388	\$178,666 \$446,666	\$178,666 \$446,666	\$1,345,720		
CIFF (rough SCI projection) UBS (rough SCI projection)	\$178,666	\$178,666	\$178,666 \$446,666			
UBS (rough SCI projection)	\$178,666 \$452,388 \$75,699	\$178,666 \$446,666 \$0	\$178,666 \$446,666 \$0	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total	\$178,666 \$452,388 \$75,699 \$11,029,833	\$178,666 \$446,666 \$0 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751	\$1,345,720		
UBS (rough SCI projection)	\$178,666 \$452,388 \$75,699	\$178,666 \$446,666 \$0	\$178,666 \$446,666 \$0	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total	\$178,666 \$452,388 \$75,699 \$11,029,833	\$178,666 \$446,666 \$0 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172	\$178,666 \$446,666 \$0 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue % of unrestricted revenue attributed to GiveWell	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172	\$178,666 \$446,666 \$0 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue % of unrestricted revenue attributed to GiveWell	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172 88%	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$178,686 \$446,666 \$0 \$0 \$9,134,751 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue % of unrestricted revenue attributed to GiveWell DFID End Fund	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172 88%	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue % of unrestricted revenue attributed to GiveWell DFID End Fund CIFF	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172 88% £5,000,000 £133,333	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751 £5,000,000 £133,333	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$1,345,720 \$75,699		
UBS (rough SCI projection) Total Of which, revenue % of unrestricted revenue attributed to GiveWell DFID End Fund	\$178,666 \$452,388 \$75,699 \$11,029,833 \$10,193,172 88%	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$178,666 \$446,666 \$0 \$9,134,751 \$9,134,751	\$1,345,720 \$75,699		

Source:	http://www.givewell.	org/files/DWDA%20	2009/SCI/SCI Give	Well Funding Scena	arios 2018-2021.x	lsx								
								Exchange rate as	1.34					
Brook to the contract of the c														
Direct implementation costs Country	# SAC requiring treatment		Cost/treatment for school-based program 2019/20		How many additional adults to treat to follow WHO control guidelines?	Approximate total cost over 3 years (no adult treatments)	Total cost over 3 years ('morbidity control' scenario) and expansion countries	Probability of non-funding bottlenecks that prevent SCI from deliving treatments	Notes on non- funding bottlenecks	Total # of people at risk (includes adults in moderate and high risk zones)	Total budget 2018/19 with adults	Total budget 2019/20 with adults	Total budget 2020/21 with adults	Additional cos of including adults
Burundi	981,232				Unknown	£545,920	£1,170,899	10%	Well-established pro	2,891,109	£619,485	£619,485	£619,485	£1,312,53
Cote D'Ivoire	2,785,116	£0.18			Unknown	£1,549,533	£1,633,280	10%		4,671,393	£1,067,204	£1,067,204	£856,991	£1,441,86
DRC	9,764,256	£0.18	£0.19	£0.19	Unknown	£5,432,461	£5,272,698	50%	SCI notes that this i	13,421,001	£2,854,590	£2,854,590	£2,854,590	£3,131,30
Ethiopia	12,593,543	£0.18	£0.19	£0.19	Unknown	£7,006,569	£6,800,513	10%	Well-established pro	23,825,551	£2,773,872	£2,773,872	£2,773,872	£1,315,04
Liberia	433,074	£0.18	£0.19	£0.19	Unknown	£240,946	£233,860	10%		1,117,994	£283,429	£283,429	£283,429	£609,34
Madagascar	3,818,332	£0.18	£0.19	£0.19	Unknown	£2,124,375	£2,061,899	10%		9,277,554	£2,325,066	£2,325,066	£2,325,066	£4,850,82
Malawi	3,188,205	£0.18	£0.19	£0.19	Unknown	£1,773,796	£2,146,656	10%		7,399,276	£1,837,198	£1,837,198	£1,504,231	£3,404,83
Mauritania	401,397	£0.18	£0.19	£0.19	Unknown	£223,322	£216,754	10%	-	573,424	£123,860	£123,860	£123,860	£148,25
Mozambique	5,388,277	£0.18	£0.19	£0.19	Unknown	£2,997,833	£3,729,129	10%		13,254,439	£3,329,738	£3,329,738	£2,733,289	£6,394,93
Niger	2,318,246	£0.18	£0.19	£0.19	Unknown	£1,289,784	£1,331,469	10%		3,385,871	£737,572	£585,208	£585,208	£618,20
Nigeria	4,524,241	£0.18	£0.19	£0.19	Unknown	£2,517,116	£2,443,090	50%	Some of this funding	16,158,010	£4,304,494	£4,304,494	£4,304,494	£10,396,36
Sudan	4,870,608	£0.18	£0.19	£0.19	Unknown	£2,709,821	£2,630,128	10%	Well-established pro	8,737,953	£2,036,913	£2,036,913	£2,036,913	£3,400,91
Uganda	5,561,730	£0.18	£0.19	£0.19	Unknown	£3,094,335	£4,562,646	10%		13,190,870	£2,102,675	£2,696,264	£2,696,264	£4,400,86
Tanzania	5,148,093	£0.18	£0.19	£0.19	Unknown	£2,864,203	£4,382,668	10%		12,800,043	£3,222,242	£2,646,240	£2,646,240	£5,650,51
Zambia	2,872,850	£0.18	£0.19	£0.19	Unknown	£1,598,345	£1,551,339	10%		4,452,018	£990,863	£990,863	£990,863	£1,374,24
Sub-total for current countries of op-	eration (GBP)					£35,968,358	£40,167,031							£48,450,06
Sub-total for current countries of op-	eration (USD)					\$48,197,600	\$53,823,821							\$64,923,08
Sub-total for current countries of op-		funding bottlenecks ((USD)			\$39,116,867	\$44,305,776							\$51,179,94
Chad	2,069,534	£0.27 [14]	£0.28	£0.29	Unknown	£1,727,115	£1,727,115	50%	Proposed potential	3,239,149	N/A	N/A	N/A	N/A
Eritrea	240,576	£0.27	£0.28	£0.29	Unknown	£200,771	£200,771	50%		322,781	N/A	N/A	N/A	N/A
Gabon	174,530	£0.27	£0.28	£0.29	Unknown	£145,653	£145,653	50%		343,554	N/A	N/A	N/A	N/A
Swaziland	161,527	£0.27	£0.28	£0.29	Unknown	£134,801	£134,801	50%		320,693	N/A	N/A	N/A	N/A
Sub-total, including expansion cour	ntries (GBP)					£38,176,698	£42,375,371							
Sub-total, including expansion cour	ntries (USD)					\$51,156,776	\$56,782,997							
Sub-total, including expantion coun	tries, after discount for non-fur	nding bottlenecks				\$40,596,455	\$45,785,364							
Other costs [15]														
	2018/19	2019/20	2020/21	Total										
Research costs	£780,000	£803,400	£827,502	£2,410,902										
Central costs	£2,459,577	£2,533,365	£2,609,366	£7,602,308										
Add to reserves	£2,654,065	£0	£0	£2,654,065										
All costs														
Total for 3 years (discounted for no	n-funding bottlenecks; excluding	ng adults)		\$57,570,603										
Total projected funding				\$29,299,334										
Difference				\$28,271,269										
Total for 3 years (discounted for no plus expansion countries)	n-funding bottlenecks; some ac	dults – SCI's 'morbid	ity control scenario	\$62,759,513										
Total projected funding				\$29,299,334										
Difference				\$33,460,178										
Total for 3 years (discounted for no	n-funding bottlenecks; including	g adults according to	WHO guidelines)	\$108,750,544										
Total projected funding				\$29,299,334										
Difference				\$79,451,210										

SCI Schistosomiasis Control Initiative						Added by GiveWell
Control Initiative						
Imperial College London						
REDUCED SCENARIO - SAC Morbidity Control a	and Targeted Adults		Control of morbidity	Reassessment after 5 rounds of treatment	Elimination as a PHP	
Current SCI-Supported Countries only						

current sci-supported co	untiles only								
			African Countries	Cost for Schisto Treatm	nent in GBP				
	WHO At Risk Data 2015		2018/19		2019	9/20	2020	Total cost over 3 years	
Country	# SAC requiring treatment	# of people at risk	Delivery Cost	TOTAL COST	Delivery Cost	TOTAL COST	Delivery Cost	TOTAL COST	
Burundi	981,232	2,891,109	£390,300	£390,300	£390,300	£390,300	£390,300	£390,300	£1,170,89
Côte d'Ivoire	2,785,116	4,671,393	£501,321	£501,321	£501,321	£501,321	£630,638	£630,638	£1,633,28
Democratic Republic of the Congo	9,764,256	13,421,001	£1,757,566	£1,757,566	£1,757,566	£1,757,566	£1,757,566	£1,757,566	£5,272,698
Ethiopia	12,593,543	23,825,551	£2,266,838	£2,266,838	£2,266,838	£2,266,838	£2,266,838	£2,266,838	£6,800,513
Liberia	433,074	1,117,994	£77,953	£77,953	£77,953	£77,953	£77,953	£77,953	£233,86
Madagascar	3,818,332	9,277,554	£687,300	£687,300	£687,300	£687,300	£687,300	£687,300	£2,061,89
Malawi	3,188,205	7,399,276	£573,877	£573,877	£573,877	£573,877	£998,902	£998,902	£2,146,65
Mauritania	401,397	573,424	£72,251	£72,251	£72,251	£72,251	£72,251	£72,251	£216,75
Mozambique	5,388,277	13,254,439	£969,890	£969,890	£969,890	£969,890	£1,789,349	£1,789,349	£3,729,12
Niger	2,318,246	3,385,871	£417,284	£417,284	£457,093	£457,093	£457,093	£457,093	£1,331,46
Nigeria	4,524,241	16,158,010	£814,363	£814,363	£814,363	£814,363	£814,363	£814,363	£2,443,09
Sudan	4,870,608	8,737,953	£876,709	£876,709	£876,709	£876,709	£876,709	£876,709	£2,630,12
Uganda	5,561,730	13,190,870	£1,001,111	£1,001,111	£1,780,767	£1,780,767	£1,780,767	£1,780,767	£4,562,64
United Republic of Tanzania	5,148,093	12,800,043	£926,657	£926,657	£1,728,006	£1,728,006	£1,728,006	£1,728,006	£4,382,66
Zambia	2,872,850	4,452,018	£517,113	£517,113	£517,113	£517,113	£517,113	£517,113	£1,551,33
TOTAL	64,649,200	135,156,506	£11,850,534	£11,850,534	£13,471,347	13,471,347	£14,845,149	£14,845,149	£40,167,03
Total with inflation 3% year on year									

- [1] In a copy of this spreadsheet, SCI stated this as £13,252,341. We converted to USD at an exchange rate of 1.301 on June 30, 2017 (from OFX, retrieved September 2017)
- [2] In a copy of this spreadsheet, SCI stated this as £11,348,420. We converted to USD at an exchange rate of 1.301 on June 30, 2017 (from OFX, retrieved September 2017)
- [3] In a copy of this spreadsheet, SCI stated this as £1,260,831. We converted to USD at an exchange rate of 1.301 on June 30, 2017 (from OFX, retrieved September 2017)
- [4] In a copy of this spreadsheet, SCI stated this as £12,521,072 for the period July 1, 2016 to February 28, 2017 (date mis-match due to a spreadsheet error). We converted to USD at an average exchange rate of 1.272 over the period July 1, 2016 to January 31, 2017 (from OFX, retrieved September 2017). We deflate this by 5% to account for the mistaken inclusion of February, which tends to be a low volume month for donations compared to November to January.
- [5] Response from SCI
- [6] This is an SCI estimate. In a copy of this spreadsheet, SCI stated this as £11,023,705 for the period July 1, 2016 to February 28, 2017 (date mis-match due to a spreadsheet error). We converted to USD at an average exchange rate of 1.272 over the period July 1, 2016 to January 31, 2017 (from OFX, retrieved September 2017). We deflate this by 5% to account for the mistaken inclusion of February, which tends to be a low volume month for donations compared to November to January.
- [7] Total excluding Good Ventures in the same period in the previous year was \$1.26M. We assume that a portion of this was due to the recommendation that was on our website from December to April that SCI receive 25% of donors' gifts. We roughly guess that 1/4 of giving was due to that recommendation specifically.
- [8] From OFX, https://www.ofx.com/en-us/forex-news/historical-exchange-rates/, retrieved September 27, 2017
- [9] From OFX, https://www.ofx.com/en-us/forex-news/historical-exchange-rates/, retrieved September 27, 2017
- [10] www.givewell.org/files/DWDA% 202009/SCI/SCI_GiveWell_Funding_Scenario_Notes_and_Assumptions.pdf, See Table 1, Pg. 1.
- [11] SCI told us that it estimates 3% inflation per year
- [12] "DRC Target population assumes total funding requirement for national coverage. The MoH is working on developing a plan for treatments by funder therefore SCI proportion is expecting to reduce according to MoH requirements. This will be updated when available." www.givewell.org/files/DWDA% 202009/SCI/SCI GiveWell Funding Scenario Notes and Assumptions.pdf, Pg. 1-2.
- [13] SCI notes, "Nigeria Target population: Consolidates the 5 states in which SCI funding is leverage to reach full coverage of all endemic LGAs and including a 6th state, Osun, over the 3 year period." Source: www.givewell.org/files/DWDA%202009/SCI/SCI_GiveWell_Funding_Scenario_Notes_and_Assumptions. pdf, Pg. 2.
- [14] Assumes a higher initial cost per treatment in the first year of implementation at £0.27", www.givewell. org/files/DWDA%202009/SCI/SCI GiveWell Funding Scenario Notes and Assumptions.pdf, Pg. 2.
- [15] Source: www.givewell.org/files/DWDA%202009/SCI/SCI_3-Year_Budget_September_2017_Redacted. xlsx, sheet "summary"